Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Enhanced therapeutic effectiveness and reduced side effects
3.2.1.2 Rising prevalence of chronic disease
3.2.1.3 Growing investment in research and development of biobetters
3.2.2 Industry pitfalls & challenges
3.2.2.1 High development costs
3.2.2.2 Stringent regulatory scenario
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technology landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Gap analysis
3.8 Porter’s analysis
3.9 PESTLE analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Erythropoietin biobetters
5.3 Insulin biobetters
5.4 G-CSF biobetters
5.5 Monoclonal antibodies biobetters
5.6 Antihemophilic factor
5.7 Other drug classes
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Cancer
6.3 Diabetes
6.4 Renal disease
6.5 Neurodegenerative disease
6.6 Genetic disorders
6.7 Other applications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Subcutaneous
7.3 Intravenous
7.4 Other routes of administration
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Amgen Inc.
10.3 AstraZeneca PLC
10.4 Biogen Inc.
10.5 Bristol-Myers Squibb Company
10.6 Celltrion Inc.
10.7 Eli Lilly And Company
10.8 F. Hoffmann-La Roche Ltd.
10.9 GSK plc
10.10 Kiniksa Pharmaceuticals, Ltd.
10.11 Merck & Co., Inc.
10.12 Novo Nordisk A/S
10.13 Regeneron Pharmaceuticals, Inc.
10.14 Sanofi
10.15 Teva Pharmaceutical Industries Limited
